Randomized, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of MK-8808 versus MabThera in Patients with Advanced CD20-Positive Follicular Lymphoma.

Trial Profile

Randomized, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of MK-8808 versus MabThera in Patients with Advanced CD20-Positive Follicular Lymphoma.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 16 Jul 2013

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Prednisone; Vincristine
  • Indications Follicular lymphoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms SAME
  • Most Recent Events

    • 16 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top